2026 Critical Care Congress Skip to main content
2026 Critical Care Congress Main banner
Final Program


Advance Program
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Session Icons
Thought Leader Session
Thought Leader Session
Guidelines Session
Guidelines Session
Aging Adult Track
Aging Adult Track
Additional Registration Fee
Additional Registration Fee

Research Snapshot Theater: Neuroscience, Adult II

Evaluation of Fludrocortisone Dosing in Neurologic Emergencies (SALT-TID)

Sunday, March 22, 2026
11:00 AM - 12:00 PM Central Time
Location: Connections Central - RST 06

  • Alexandra Ross, PharmD

    Disclosure(s): No relevant financial relationship(s) to disclose.

  • KL

    Kristen Looney, PharmD

    Neuro-Critical Care Clinical Pharmacy Specialist
    University of Cincinnati Medical Center

    Disclosure information not submitted.

  • AH

    Abigail Hoff, PharmD

    Clinical Pharmacy Specialist, Internal Medicine/Neurosciences
    University of Cincinnati Medical Center

    Disclosure information not submitted.

  • LD

    Lauren Dehne, PharmD, BCCCP

    Clinical Pharmacy Specialist, Surgical and Medical Intensive Care Unit
    University of Cincinnati Medical Center

    Disclosure information not submitted.

  • MF

    Madeline Foertsch, PharmD, BCCCP, BCPS

    Clinical Pharmacy Specialist, Neuro-Critical Care
    University of Cincinnati Medical Center

    Disclosure information not submitted.

Introduction: Mineralocorticoids are often used to reduce natriuresis therefore decreasing sodium and fluid replacement in patients with aneurysmal subarachnoid hemorrhages. There is a lack of data for best dosing strategy in all neurologic emergencies. This study aims to evaluate the efficacy and compare different doses of fludrocortisone utilized for hyponatremia in all neurologic emergencies.


Methods: This single-health system, retrospective, cohort study included adult patients admitted to a neurocritical care or neurosurgery unit who received high dose (> 0.3 mg/day, HD) or low dose (≤ 0.3 mg/day, LD) fludrocortisone for hyponatremia due to a neurologic emergency. The primary outcome was the change in sodium levels with LD versus HD fludrocortisone within 24 hours after reaching target dose. Secondary outcomes included fluid balance, hypokalemia, serum sodium levels, the dose and duration of other therapies targeting hyponatremia, hospital and ICU length of stay, and all-cause mortality.


Results: 108 patients were included in analysis (LD n=51; HD n=57). There was no significant difference in the change in serum sodium levels (LD 4 mEq/L [1-6] vs HD 5 [1.75-7] mEq/L; p=0.31). There was a significantly lower net fluid balance in the HD group 24 hours prior to target dose (LD 257 mL/day [-668.7-679.9] vs HD -379.6 mL/day [-895.7-229.5]; p=0.03). Most patients required potassium replacement, with significantly higher doses in the HD group (80 mEq [20-120] vs 137 mEq [61-200]; p=0.002). Duration of salt tablets (LD 8 days [4-11] vs HD 10 days [7-14]; p=0.04) and sodium chloride infusions (LD 3 days [1-5] vs HD 6 days [2-10], p=0.005) were longer in the HD group. Dosing of salt tablets or sodium chloride infusions did not differ between therapies. A multivariate logistic regression for predictors of response to fludrocortisone showed that patients who received hypertonic saline (OR 2.84 [1.01-7.97]) or had a sodium level < 130 mEq prior to the maximum fludrocortisone dose (OR 6.54 [1.64-26.1]) were more likely to be responders.


Conclusions: There was no significant difference in the change in serum sodium levels between patients that received LD and HD fludrocortisone for a neurologic emergency. More investigation is warranted into different dosing strategies of fludrocortisone for neurologic emergencies.